Goodpasture's Syndrome: Characteristics, Treatment, and Management

Key Characteristics and Diagnosis

Goodpasture's syndrome is characterized by anti-glomerular basement membrane (anti-GBM) antibodies causing damage to both pulmonary and renal systems, classically presenting as a pulmonary-renal syndrome, and is definitively an autoimmune disease where antibodies target the noncollagenous (NC1) domain of the α3 chain of type IV collagen present in glomerular and alveolar basement membranes 1.
Diagnosis should be made without delay in all patients with suspected rapidly progressive glomerulonephritis (RPGN), and laboratory testing includes anti-GBM antibodies, which are positive in most cases, though approximately 10% may be falsely negative 1.
Kidney biopsy typically shows necrotizing and crescentic glomerulonephritis with linear immunofluorescent staining for IgG on the GBM 2.

Immediate aggressive treatment is recommended with cyclophosphamide, corticosteroids, and plasmapheresis for all patients with anti-GBM GN except those who are dialysis-dependent at presentation, have 100% crescents or >50% global glomerulosclerosis on biopsy, and do not have pulmonary hemorrhage 3, 4.
Treatment should begin without delay once the diagnosis is confirmed; if highly suspected, it's appropriate to begin high-dose corticosteroids and plasmapheresis while awaiting confirmation 3.
Dialysis may be required as treatment, particularly in patients with severe kidney injury at presentation 1, 3.
Kidney transplantation should be deferred until anti-GBM antibodies have been undetectable for a minimum of 6 months 3.

Some patients may have both anti-GBM antibodies and ANCA (double-positive), requiring careful treatment consideration 3.
Relapses are rare but have been reported, necessitating ongoing monitoring for at least the first 2 years 3.

Patients with Goodpasture syndrome should be managed at centers with experience in rapidly progressive glomerulonephritis and immediate access to plasmapheresis, as recommended by specialized clinical guidelines 5, 6
Dedicated hospital beds under nephrology service are essential for initial aggressive treatment and managing complications, according to clinical recommendations 5, 6
A designated coordinator, typically a specialized nurse, should manage the complex treatment schedule involving plasmapheresis sessions, immunosuppression administration, and monitoring, as suggested by clinical guidelines 5, 6

The American Thoracic Society recommends distinguishing Goodpasture syndrome from other pulmonary-renal syndromes by linear immunofluorescent staining for IgG on the glomerular basement membrane, which is pathognomonic 7, 8, 9

The European Respiratory Society advises against confusing Goodpasture syndrome with hypersensitivity pneumonitis, despite chemical exposure history, as HP presents with lymphocytic BAL and granulomas, not linear IgG staining 7, 8, 9